Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.

Abstract

A new drug, pirifibrate, was investigated in a multicenter study of 100 patients with type IIa, IIb, or IV hyperlipoproteinemia (HLP). After one month of dieting, patients completed six months of treatment with a dose of 1,500 mg/day of pirifibrate. An average fall of about 20% in plasma cholesterol was observed in type IIa and IIb HLP, and more than 50% in the triglycerides in type IIb and IV HLP. Both reductions were statistically significant (P less than 0.00005). Increases in the alpha-lipoproteins were observed in the three types of HLP. The pre-beta-lipoproteins showed a statistically significant fall in type IIb and IV HLP. Variations observed in beta-lipoproteins were significant only in some controls with type IV, HLP, who had low basal levels.

• Authors: V Bonora, R J Calalabuig, E Caviola, J Soler, J M Pueyo, T Micaló, R P Cano
• Journal: Clinical therapeutics (Clin Ther) Vol. 4 Issue 3 Pg. 192-200 ( 1981) ISSN: 0149-2918 [Print] United States
• PMID: 7030489 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Propionates
• Triglycerides
• Clofibric Acid
• pirifibrate

Topics

• Adolescent
• Adult
• Aged
• Clinical Trials as Topic
• Clofibric Acid
• Humans
• Hyperlipoproteinemia Type II (blood, drug therapy)
• Hyperlipoproteinemia Type IV (blood, drug therapy)
• Middle Aged
• Propionates (therapeutic use)
• Triglycerides (blood)